> top > docs > PubMed:27172902 > spans > 766-1053 > annotations

PubMed:27172902 / 766-1053 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

Id Subject Object Predicate Lexical cue
T5 0-287 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.

LitCoin-entities

Id Subject Object Predicate Lexical cue db_id
11296 30-33 GeneOrGeneProduct denotes TLR NCBIGene:13982
11297 44-53 ChemicalEntity denotes cisplatin MESH:D002945
11298 92-97 GeneOrGeneProduct denotes IL-10 NCBIGene:16153
11299 135-143 GeneOrGeneProduct denotes p38 MAPK NCBIGene:26416
11300 148-153 GeneOrGeneProduct denotes NF-κB NCBIGene:18033
11301 204-209 GeneOrGeneProduct denotes TNF-α NCBIGene:21926
11302 214-222 GeneOrGeneProduct denotes IL-12p70 NCBIGene:16185
11303 239-248 ChemicalEntity denotes cisplatin MESH:D002945

LitCoin-GeneOrGeneProduct-v0

Id Subject Object Predicate Lexical cue
T26 44-53 GeneOrGeneProduct denotes cisplatin
T27 73-81 GeneOrGeneProduct denotes markedly
T28 92-97 GeneOrGeneProduct denotes IL-10
T29 98-108 GeneOrGeneProduct denotes production
T30 117-127 GeneOrGeneProduct denotes activation
T31 135-143 GeneOrGeneProduct denotes p38 MAPK
T32 239-248 GeneOrGeneProduct denotes cisplatin
T33 249-257 GeneOrGeneProduct denotes mediated

LitCoin-GeneOrGeneProduct-v2

Id Subject Object Predicate Lexical cue
T14 44-53 GeneOrGeneProduct denotes cisplatin
T15 92-97 GeneOrGeneProduct denotes IL-10
T16 135-143 GeneOrGeneProduct denotes p38 MAPK
T17 239-248 GeneOrGeneProduct denotes cisplatin

LitCoin-GeneOrGeneProduct-v3

Id Subject Object Predicate Lexical cue
T8 30-33 GeneOrGeneProduct denotes TLR
T9 92-97 GeneOrGeneProduct denotes IL-10
T10 135-143 GeneOrGeneProduct denotes p38 MAPK

LitCoin_Mondo_095

Id Subject Object Predicate Lexical cue mondo_id
T4 62-65 DiseaseOrPhenotypicFeature denotes DCs 0010155
T5 283-286 DiseaseOrPhenotypicFeature denotes DCs 0010155

LitCoin-Chemical-MeSH-CHEBI

Id Subject Object Predicate Lexical cue ID:
T11 44-53 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899
T13 239-248 ChemicalEntity denotes cisplatin D002945|http://purl.obolibrary.org/obo/CHEBI_27899

LitCoin-training-merged

Id Subject Object Predicate Lexical cue ID:
T13 239-248 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T11 44-53 ChemicalEntity denotes cisplatin http://purl.obolibrary.org/obo/CHEBI_27899|D002945
T92895 135-143 GeneOrGeneProduct denotes p38 MAPK
T9 92-97 GeneOrGeneProduct denotes IL-10
T5090 30-33 GeneOrGeneProduct denotes TLR

Inflammaging

Id Subject Object Predicate Lexical cue
T5 0-287 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.
T5 0-287 Sentence denotes Upon stimulation with various TLR agonists, cisplatin-treated DCs showed markedly increased IL-10 production through activation of the p38 MAPK and NF-κB signaling pathways without altering the levels of TNF-α and IL-12p70, indicating the cisplatin-mediated induction of tolerogenic DCs.